To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson’s disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
PINK1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PINK1, including:
- -A217D (heterozygous and homozygous)
- -M313I (heterozygous and homozygous) - in development, est late 2025
- -L347P (heterozygous and homozygous) - in development, est late 2025
- -P399L (heterozygous and homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
SCARB2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SCARB2, including
- -R424* (heterozygous and homozygous) - in development, est late 2025
- -W146Sfs*15 (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
MCI-PARK Mouse*
Mouse Model
Homozygous knockout mice targeting Ndufs2 (NADH:ubquinone oxidoreductase core subunit S2) specifically in dopaminergic neurons. Mice with floxed Ndufs2 allele were crossed with mice expressing Cre recombinase under the control of Slc6ac (dopamine transporter; DAT) promoter. Model was generated by D. James Surmeier at Northwestern University and deposited through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative. RRID:IMSR_JAX:036313
A2a-Flp Mouse*
Mouse Model
A2a-FlpO knock-in mice express optimized Flp recombinase (FlpO) from the mouse Adora2a promoter and enable the targeting of Adora2a-expressing cells and the indirect pathway spiny projection neuronal (iSPN) subpopulation of neurons in the striatum. Model was generated and deposited by Dr. Rui Costa at Allen Institute through the MJFF Sponsored Tools Program, and supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
SNCA A53T Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with SNCA A53T mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
SNCA A30P Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with SNCA A30P mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
LRRK2 G2019S Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with LRRK2 G2019S mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
DJ-1 Exon 1-5 Deletion Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with DJ-1 Exon 1-5 deletion. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
GBA IVS2+1 Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with GBA IVS2+1 mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
Parkin Exon 3 Deletion Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with PRKN Exon 3 deletion. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
Have questions or need additional information?
Email [email protected] with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic